Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Down 2.2 %

Shares of LPCN opened at $3.05 on Tuesday. Lipocine has a twelve month low of $2.75 and a twelve month high of $11.79. The firm has a market capitalization of $16.32 million, a P/E ratio of -4.01 and a beta of 1.51. The firm’s 50-day moving average is $3.29 and its two-hundred day moving average is $4.37.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.